<DOC>
	<DOCNO>NCT02089048</DOCNO>
	<brief_summary>Phase I , open-label study 15 healthy adult subject receive 6 mg auranofin orally every 24 hour 7days . Blood sample take 17 week follow last dose auranofin determination terminal phase pharmacokinetic parameter . Stool sample also obtain measurement gold .</brief_summary>
	<brief_title>Auranofin PK Following Oral Dose Administration</brief_title>
	<detailed_description>Auranofin gold-containing chemical salt , grant orphan drug status use treatment amebiasis . Amebiasis parasitic infection cause protozoon Entamoeba histolytica . It affect ten percent world 's population , especially common area poor health infrastructure . This Phase I open label , multiple dose study evaluate pharmacokinetics Auranofin follow oral dose administration 7 day healthy subject . 15 healthy male female volunteer age 18-45 year , inclusive enrol one site . The study duration 48 week 23 week subject participation . The primary objective characterizes pharmacokinetics gold , give auranofin , 7 day daily oral dose administration . The secondary objective monitor safety Auranofin 7 day oral administration .</detailed_description>
	<mesh_term>Amebiasis</mesh_term>
	<mesh_term>Dysentery , Amebic</mesh_term>
	<mesh_term>Auranofin</mesh_term>
	<criteria>Personally sign date informed consent document . Healthy male female nonchildbearing potential , age 18 45 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , complete physical examination include vital sign , clinical laboratory test . Nonchildbearing potential define amenorrheic least 2 year plus serum folliclestimulating hormone ( FSH ) level &gt; 30 IU/L , document bilateral oophorectomy and/or hysterectomy , tubal ligation . Body mass index ( BMI ) 18 30 [ weight ( kg ) ] / [ height ( ) ^2 ] inclusive ; total body weight &gt; 50 kg ( 110 lb ) &lt; 122 kg ( 250 lb ) Screening Visit . Male subject willing use appropriate contraception duration study . Willing able comply schedule visit , dose plan , laboratory test , study procedure . Evidence history clinically significant hematologic , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , musculoskeletal , immunologic , neurologic dermatologic disease ( include drug allergy clinically significant ) opinion Investigator could impact participation subject study assessment study endpoint . Current evidence history malignancy ( except completely treat cervical cancer situ intraductal carcinoma breast , &lt; /= 2 basal cell and/or squamous cell carcinoma skin completely excise ) 5 year prior Day 1 evidence recurrence . Breastfeeding positive serum pregnancy test Screening Visit Day 1 . History drug abuse within 6 month prior study drug administration . A history alcohol abuse , define regular alcohol consumption exceed 7 drinks/week female 14 drinks/week men ( 1 drink = 5 ounce [ 150 mL ] wine 12 ounce [ 360 mL ] beer 1.5 ounce [ 45 mL ] hard liquor ) , within 6 month prior study drug administration . Positive result standard urine drug screen ( Screening Visit Day 1 ) positive test alcohol ( Screening visit Day 1 ) . Daily use tobacco nicotinecontaining product ( cigarette , pipe , cigar , chew tobacco nicotine gum , lozenges patch ) . Occasional social smoking acceptable . You must change use tobacco first visit completion last visit study . Treatment investigational drug within 30 day prior study drug administration . Prior exposure goldcontaining product . Use prescription nonprescription drug , vitamin , dietary herbal supplement within 14 day prior study drug administration . As exception , acetaminophen may use dos &lt; /=1 g/day 24 hour prior study drug administration . Blood donation &gt; /= 1 pint ( 473 mL ) within 30 day prior study drug administration . Plasma platelet donation within 14 day prior study drug administration . Screening liver function test ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] ) great upper limit normal ( ULN ) . Evidence hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) infection upon serological test Screening Visit . Evidence active infection febrile illness ( e.g. , bronchopulmonary , urinary gastrointestinal ) within 7 day prior study drug administration . History allergy auranofin excipients capsule . ( excipients per package insert auranofin list Section 6.1 ) Any condition , opinion investigator , pose risk safety individual valid conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Amebiasis , auranofin , pharmokinetics , pharmacodynamics</keyword>
</DOC>